Newsbenzinga
Agomab Therapeutics Doses First Patient In NOV-ERA, Global Phase 2b Study Evaluating Ontunisertib In Patients With Symptomatic FSCD
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…